We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Samsung BioLogics has faced accounting scrutiny for nearly a year on its biosimilars joint venture with Biogen, and now the investigation has taken a new turn.